Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17527085 | 0.99 | CDK1 (0.62) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL19399297 | 0.95 | CDK1 (0.60) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL23904665 | 0.93 | CCR1 (0.66) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL23340186 | 0.86 | FERMT2 (0.56) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL19399296 | 0.84 | CCR1 (0.82) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL2443305 | 0.84 | ANPEP (0.63) | — | |
| SCHEMBL17527086 | 0.83 | CCR1 (0.79) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL22735631 | 0.82 | FERMT2 (0.52) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL11752215 | 0.80 | CDK1 (0.87) | CDK1FERMT2CCR1NR4A2KDM4E | |
| SCHEMBL16596384 | 0.79 | HTR1A (0.61) | FERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220064118-A1 | Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| EP-3848355-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | The Trustees Of The University Of Pennsylvania (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11001558-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3177595-B1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | UNIV PENNSYLVANIA (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20190248747-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-08-15 | — | — | US | disclosed |
| US-10221140-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170275252-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275252-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2016022956-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | CDK1 138/4885FERMT2 3692/4885CCR1 4807/4885 |
| US-11001558-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | CDK1 138/4885FERMT2 3692/4885CCR1 4807/4885 |
| US-20220064118-A1 | Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy | SQSTM1, ATG7, BECN1 | CDK1 138/4885FERMT2 3692/4885CCR1 4807/4885 |
| US-20190248747-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | SQSTM1, ATG7, BECN1 | CDK1 138/4885FERMT2 3692/4885CCR1 4807/4885 |
| US-20170275252-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | SQSTM1, ATG7, BECN1 | CDK1 138/4885FERMT2 3692/4885CCR1 4807/4885 |
| US-10221140-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | CDK1 138/4885FERMT2 3692/4885CCR1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.